To: All Concerned Parties | November 24, 2021 |
Company Name: Solasia Pharma K.K. | |
Representative: | Yoshihiro Arai, President & CEO |
(Code number: | 4597, TSE Mothers Section) |
Contact: | Toshio Miyashita, CFO, Director |
Tel: | 81-3-5843-8045 |
URL: | https://solasia.co.jp/en/ |
Solasia's Partner, Isofol Receives FDA Fast Track Designation
for arfolitixorin (SP-05) in Advanced Colorectal Cancer
Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the development of the drug candidate arfolitixorin (SP-05), the stabilized and biologically active pure form of folate ([6R]- MTHF), for treatment of patients with metastatic colorectal cancer (mCRC).
For more information, please refer to the Isofol´s website. Link
###
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Solasia Pharma KK published this content on 24 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 November 2021 10:29:03 UTC.